Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hackensack Meridian Health
Massachusetts General Hospital
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Chicago
University of Washington
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
Eli Lilly and Company
University of Ulm
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
University of Ulm
Memorial Sloan Kettering Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Janssen Pharmaceutical K.K.
Peking Union Medical College Hospital
University College, London
Institute of Hematology & Blood Diseases Hospital, China
University of Ulm
University College, London
City of Hope Medical Center
Kosin University Gospel Hospital
Shanghai Changzheng Hospital
University of Nebraska
Eastern Cooperative Oncology Group
Abramson Cancer Center at Penn Medicine
Brown University
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Northwestern University
University College, London
University of Athens
Dana-Farber Cancer Institute
Pharmacyclics LLC.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
University of Washington
University of Arizona
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Swiss Cancer Institute
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute